LynkuetTM (elinzanetant) receives first global approval in UK for moderate to severe menopause-related hot flashes, based on OASIS trials. It's the first dual neurokinin-targeted therapy.
ST Engineering and NHG Health partner to co-develop engineering and smart systems, enhancing patient care and optimizing health service delivery for 1.5 million Singapore residents.
BlueRock’s OpCT-001, the first iPSC-derived therapy for photoreceptor diseases, enters Phase 1/2a CLARICO trial to assess safety and impact on vision loss.
Cardinal Health advances care by connecting clinical and supply chain teams with WaveMark Solutions, streamlining inventory, reducing waste, and improving patient outcomes.